Aprea Therapeutics Inc (APRE)
$4.33
Live
Performance
- $4.31$4.54$4.33
0.46%
Downside
Day's Volatility :5.07%
Upside
4.63%
- $2.15$8.85$4.33
50.34%
Downside
52 Weeks Volatility :75.7%
Upside
51.05%
Returns
| Period | Aprea Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 10.55% | 0.0% |
6 Months | -14.06% | 0.0% |
1 Year | 12.68% | 0.0% |
3 Years | -95.69% | -23.0% |
Highlights
Market Capitalization | 30.7M |
Book Value | $4.71 |
Earnings Per Share (EPS) | -3.01 |
Wall Street Target Price | 15.67 |
Profit Margin | 0.0% |
Operating Margin TTM | -685.03% |
Return On Assets TTM | -30.26% |
Return On Equity TTM | -50.11% |
Revenue TTM | 1.3M |
Revenue Per Share TTM | 0.29 |
Quarterly Revenue Growth YOY | 124.9% |
Gross Profit TTM | 0.0 |
EBITDA | -14.2M |
Diluted Eps TTM | -3.01 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.73 |
EPS Estimate Next Year | -1.02 |
EPS Estimate Current Quarter | -0.63 |
EPS Estimate Next Quarter | -0.64 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 261.89%
Technicals Summary
Sell
Neutral
Buy
Aprea Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aprea Therapeutics Inc | 43.79% | -14.06% | 12.68% | -95.69% | -99.15% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aprea Therapeutics Inc | 0.48 | NA | NA | -2.73 | -0.5 | -0.3 | NA | 4.71 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aprea Therapeutics Inc | Buy | $30.7M | -99.15% | 0.48 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Aprea Therapeutics Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 75.0%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 140.5%
Institutional Holdings
AIGH Capital Management, LLC
9.93%Nantahala Capital Management, LLC
7.58%Sio Capital Management, LLC
5.09%Sphera Funds Management Ltd.
4.97%Altium Capital Management, LP
2.53%Dafna Capital Management LLC
2.53%
Company Information
annan naturvetenskaplig och teknisk forskning och utveckling
Organization | Aprea Therapeutics Inc |
Employees | 7 |
CEO | Dr. Oren Gilad Ph.D. |
Industry | Commercial Services |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$4.33
-1.59%
Invesco Bulletshares 2025 Hi
$4.33
-1.59%
Schwab International Dividend Equity Etf
$4.33
-1.59%
Blockchain Coinvestors Acquisition Corp.
$4.33
-1.59%
Allgiant Travel Company
$4.33
-1.59%
Rogers Corp
$4.33
-1.59%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$4.33
-1.59%
Iheartmedia
$4.33
-1.59%
Lightpath Technologies Inc
$4.33
-1.59%